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Fellow members of our society, I am deeply apprecia-
tive for the honor of president you have bestowed upon
me. It has been an exciting year, and my responsibilities
as president have been greatly helped by the addition of
our new executive vice president, Joann Baughman, and
also by Executive Director Elaine Strass, Jane Salomon,
Marsha Ryan, and the other able members of our ad-
ministrative office staff.
My first exposure to human genetics was a course in
January 1958 at the University of Wisconsin, which was
cotaught by a former president of our society, Jim Crow,
and his former student and the first Allen Award winner,
Newton Morton. The structure of DNA had been de-
scribed just five years earlier by Watson and Crick, and
just two years earlier, the diploid number of human chro-
mosomes was shown to be 46, to the surprise of most
scientists. A year later, it was found that Down syndrome
was caused by an extra chromosome. The ensuing 44
years have established human genetics at the forefront
of the biological sciences.
The Human Genome Initiative has not only essentially
completed the human sequence, but it has also fostered
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the development of rapid automated genotyping, allow-
ing, among other things, a larger number of polymorphic
markers to be typed and, thus, a greater coverage of the
genome. One result has been that the vast majority of
relatively common Mendelian traits have been mapped,
and most of the responsible genes have been cloned. Thus,
in the case of Mendelian disorders, the weakest link, the
paucity of markers, has been overcome, leading to the
elucidation of the genetic etiology of these disorders.
Mendelian disorders, however, are uncommon. Based
mainly on twin studies, it was clear that many of the
common disorders in humans also have a major genetic
component. Buoyed by their success in mapping Men-
delian disorders, scientists began to turn their attention
to these common disorders with great enthusiasm and
optimism. There was an urgency to proceed. Physicians
in general clinical practice rarely see a patient with a
Mendelian disorder. A large number of their clientele,
however, have a serious illness in which genetics plays
a major role. HMOs, with an emphasis on prevention,
realize the importance of knowing their patients’ risk
factors for common disorders. It soon became clear that
this endeavor, mapping and cloning genes for complex
disorders, was far and away more difficult than was first
imagined. At this juncture, I would like to make a dis-
tinction between two types of multifactorial traits. The
first involves mostly common congenital malformations,
such as cleft lip and/or palate, pyloric stenosis, and club
foot. These are dichotomous (all-or-none) attributes,
which often have a major gene involved, but are not
inherited in simple Mendelian fashion. These will not
be discussed further. The second group is known as com-
plex disorders for good reason, since both their genetic
and environmental components would seem to be more
complicated.
While multigenerational families were ideal for link-
age of Mendelian traits, their use in early linkage studies
of bipolar disorder and schizophrenia produced a great
deal of publicity for results later found to be incorrect.
There was general agreement that new approaches were
necessary, but there was no consensus on any one
method.
National Institutes of Health (NIH), in particular Na-
tional Institute of Mental Health, National Institute of
Alcohol Abuse and Alcoholism, and National Heart,
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Lung, and Blood Institute, realized that the time was
ripe to fund initiatives to find causative genes for those
common disorders, such as the psychiatric diseases, ad-
diction, hypertension, and adult diabetes. It also became
clear that a large number of subjects, whether as families,
affected sib pairs, or case-controls, were needed for ad-
equate power to detect linkage to a gene with only a
partial affect on the phenotype. Thus, any one re-
searcher would have difficulty in recruiting sufficient
subjects, and this naturally led to a large number of
collaborative efforts by scientists. The overall budgets
for these NIH-funded grants to study complex diseases
were quite high, with a large proportion being spent on
recruitment and diagnosis. In recent years, this has led
a number of institutes to demand that researchers share
their resources, DNA and/or immortalized cell lines, and
clinical data with other investigators outside the collab-
oration. This has been a controversial decision, and NIH
is still refining the rules for this sharing venture. On the
other hand, researchers realize that NIH has invested a
considerable amount of money to procure these re-
sources, and it wants to maximize the research potential
of the resource rather than invest further money in sam-
ple procurement. It may be difficult to share resources
previously collected without obtaining institutional re-
view board approval to recontact individuals for their
permission to broaden the scope of sharing. Clearly, the
best solution to enforced sharing of resources is to enter
into a collaborative agreement with the new researchers,
and, hopefully, this will become the trend in the future.
I believe that collaborative sharing is likely to be
commonplace in the near future.
As in most genetic studies, the procedure for a suc-
cessful study for positional cloning of complex disease
genes has a number of components. The first is ascer-
tainment, clinical evaluation, and sample collection from
appropriate families or cases and controls. Family as-
certainment is becoming more difficult, with new re-
strictions being placed on obtaining clinical information
on an individual from a relative. As you are aware, this
can be a major impediment to research, and ASHG is
attempting to allay fears of administrators, IRBs, and
others that the rights of family members will not be taken
into account. It is important that all of us be aware of
the sensitive nature of many familial disorders, and re-
spect the privacy of family members. On the other hand,
it is important to emphasize that family members are
usually very eager to participate and are likely to be
concerned if they perceive too many impediments lim-
iting scientific progress.
In general, three types of population samples are in
vogue, extended families, affected sib pairs (with or with-
out their parents), and case-control or transmission/dis-
equilibrium studies. Each has its proponents among the
genetics community and, due to the many possible ge-
netic mechanisms involved in complex disorders, each
may well be optimum for a specific genetic mechanism.
Thus, they should complement each other rather than
being viewed as competitors.
Probably the single most important aspect of studies
of complex disease is the phenotype, which may well be
multidimensional. It is essential that a well-thought-out
standardized protocol, which has been validated, be used
by all clinicians involved. While it may not be possible
to foresee important variables that may later be very use-
ful for defining endophenotypes, attempting to revisit
individuals for further information at a later time will
be both time consuming and expensive.
The next step in gene discovery is genotyping. While
restriction fragment length polymorphisms (RFLPs) were
useful for positional cloning of Mendelian disorders,
their limited number and expensive typing were not very
useful for the study of complex disorders. The discovery
of dinucleotide repeats by Weber and, later, the identi-
fication of other short tandem repeats (microsatellites)
allowed a 10-cM genome screen to be performed easily
and inexpensively. Thus, sufficient markers were avail-
able for gene mappers to realize that the genetic etiology
of complex traits could be dissected. Unfortunately, the
findings from numerous studies using these newmarkers
were inconclusive. Single-nucleotide polymorphisms
(SNPs) may well be the savior for complex disorders.
Their almost-limitless abundance in the human genome,
and the ever-increasing speed of high-throughput ge-
notyping, bodes well for the mapping community.
The final phase of a linkage study of a complex trait
is the statistical analysis and interpretation of the results.
Early on, it became apparent that the analytic methods
used to localize Mendelian traits were of very limited use-
fulness for complex disorders. Fortunately, many highly
capable genetic epidemiologists developed a wide variety
of statistical genetic tools to deal with large numbers of
genotypes, multiple phenotypes, and complex disease in-
heritance. These methods encompass both dichotomous
and quantitative traits. In mapping Mendelian traits,
nonreplication usually simply meant locus heterogeneity.
In complex-trait analysis, nonreplication of a linkage
finding may be due to different sets of genes acting in
different samples but also may mean that the initial pos-
itive results were artifactual, possibly due to the large
number of markers being tested. While many studies
utilize different methods as a quasireplication, hoping
to give increased weight to a specific chromosomal lo-
cation, this is not a substitute for actual replication.
For the second part of my presentation, I chose an
example of a complex disorder that is one of a number
that our group has been involved with for a number of
years, namely, addictive disorders, and I will focus on
alcohol dependence. Though per capita alcohol consump-
tion is declining, it is estimated that 20 million Ameri-
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cans have a serious drinking problem leading to early
death. Alcohol contributes to up to 50% of fatal auto-
mobile accidents.
The concordance rate for alcoholism in MZ twins is
twice that in DZ twins. Probably the most compelling
evidence that alcohol dependence is to a large extent
genetic came from a study of Swedish children adopted
at birth. In essence, offspring of an alcoholic parent were
at greater risk of alcohol dependence than children of
nonalcoholics raised in an adoptive home with an al-
coholic adopting parent. Adopted men whose biological
fathers were early-onset alcoholics had a ninefold in-
creased risk of alcoholism as compared with those with
nonalcoholic fathers. Other twin studies have demon-
strated similar findings, although the risk is typically
closer to a fourfold increase.
Early studies of alcohol susceptibility focused on the
study of candidate genes. The gene for the mitochondrial
aldehyde dehydrogenase (ALDH2),which oxidizes acetal-
dehyde, has a variant, ALDH2*2. The protein encoded
by this variant has very low or absent activity. Homo-
zygotes have no enzyme activity, while heterozygotes
have much lower activity than the normal homozygote.
Individuals with the mutant allele experience a flushing
reaction upon ingestion of only a small amount of al-
cohol (Thomasson et al. 1991). This adverse reaction
acts as a protective factor against alcoholism, and the
mutant allele has a relatively high prevalence in Asians.
There are also differences in allele frequencies at the two
alcohol dehydrogenase (ADH) loci in different racial
groups, and they also play a role in alcoholism. Extensive
association studies of the dopamine D2 receptor (DRD2)
have had mixed results. A few studies have found a
significant association between the TaqI-A1 polymor-
phism in the DRD2 gene with alcoholism (Noble et al.
1994), but a majority of researchers have been unable
to confirm this finding (Edenberg et al. 1998).
The largest genetic linkage study on alcoholism is the
Collaborative Study of the Genetics of Alcoholism
(COGA), which was initiated in 1990. The study in-
volves nine centers throughout the U.S. All are respon-
sible for recruiting families and subjects. Two, Indiana
University School of Medicine and Washington Univer-
sity, St. Louis, are responsible for molecular genotyping
and data management and analysis, and Southwestern
Foundation for Biomedical Research is also involved in
data analysis. Other sites are State University of New
York, Downstate Medical Center (New York), University
of Connecticut Health Science Center, University of Iowa
School of Medicine, University of California School of
Medicine (San Diego), and Howard University (Wash-
ington, D.C.). Initially, 105 families were evaluated and
genotyped for more than 300 microsatellite markers as
part of a genome screen. Individuals were defined as
affected if they fulfilled COGA criteria for alcoholism,
based on both DSM-III-R and Feighner criteria. A total
of 382 sib pairs met these criteria. Potential evidence of
linkage was found on chromosomes 7 (LOD score 3.5),
1 (LOD score 2.9), and 2 (LOD score 1.8). Interestingly,
additional analysis, using individuals without a diag-
nosis of alcoholism but with multiple alcoholic relatives,
suggested a locus with protective effects on chromosome
4, near the ADH loci (Foroud et al. 2000). Since the
COGA sample includes only a few Asians, this finding
suggested that the ADH protective factor is not limited
to the Asian population. Subsequently, using the phe-
notype, “maximum number of drinks ever consumed,”
linkage to chromosome 4 in the ADH region was de-
tected (Saccone et al. 2000). This region is now being
extensively studied.
A replication data set of 157 pedigrees was ascertained
and evaluated using the same diagnostic criteria and
marker set as the initial sample. This sample supported
linkage to chromosomes 1 and 7 but not to chromosome
2. A new region on chromosome 3 ( ) wasLODp 3.4
identified. It is typical of replication studies to support
some, but not all, of the previous findings. This would
suggest either that the two samples may be from different
populations or, probably more likely, the disparate re-
sults are due to a type 1 error. Amore-detailed discussion
of problems in replication is given by Suarez et al. (1994).
This two-stage approach, an initial and then a replica-
tion sample, is ideal for mapping a complex trait, and
it also gives independent assessment of marker order. As
one might expect, there are numerous candidate genes
in these broadly linked chromosomal regions, and the
regions must be further refined before embarking on a
screen of candidate genes.
It is likely that gene interaction plays a major role in
the etiology of complex disorders. To misquote a famous
phrase, “no gene is an island.” Using the COGA data set
to look for interaction (epistasis), one was discovered be-
tween loci on chromosomes 1 and 15. An analysis, hold-
ing the score on 1 constant, gave a significant score for
chromosome 15.
Another phenomenon, being investigated at the Indiana
Alcohol Research Center, is acute tolerance to alcohol.
Two measures were assessed: sensitivity (which is the in-
itial response to alcohol) and acute adaptation (which is
the recovery of a dependent measure toward baseline
while the exposure of the brain to alcohol is held con-
stant). Alcohol is infused into family-history-positive
(FHP) and family-history-negative (FHN) individuals to
obtain a breath alcohol level (BrAc) of 60 mg % over a
20-min period. A scale to measure subjective perceptions
is administered to subjects before and after this 20-min
period. This scale measures the subjects’ perception of
their level of intoxication in several dimensions. The
BrAc level is then maintained at 60 mg % for 175 min,
and the perceptions scale is administered a third time.
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The result was that FHP subjects reported greater initial
response to alcohol following the initial alcohol infusion
than FHN individuals. During the 175 minutes of con-
stant alcohol exposure, the FHP subjects developedmore
acute tolerance to alcohol, compared with the FHN sub-
jects. The majority of the measures were highly signifi-
cant (Morzorati et al. 2002).
What can the brain tell us about alcohol dependence?
Human brain oscillations, as measured by an electro-
encephalogram (EEG), are stable and are highly heri-
table. The average heritability in four frequency bands,
delta (1.5–3.5 Hz), theta (4.0–7.5 Hz), alpha (8.0–12.5
Hz), and beta (13–25 Hz) is 76%, 89%, 89%, and 86%,
respectively. Porjesz and colleagues (2002) recently stud-
ied 1,553 individuals (age range 7–70 years) from 250
COGA families. Awhole genome screen, using 351mark-
ers, was performed. The strongest evidence for linkage
was observed on chromosome 4p for beta-based traits.
Beta was divided into three components and gave LOD
scores 3.39, 5.01, and 2.17 for a region encompassing
the GABRB1 locus. This region is situated within a clus-
ter of GABAA receptor genes located on chromosome
4p, the same region implicated, independently, in the
susceptibility to alcoholism. Also, significant linkage dis-
equilibrium was found in the COGA sample, across the
GABRA2 gene, using DSM-IV criteria to define the phe-
notype for alcoholism. A significant LOD score (4.12)
was also found with a theta wave on chromosome 7 in
the region of the acetylcholine muscarinic receptor,
which is known to control theta rhythm.
To summarize this brief discussion on the genetics of
alcoholism, it was clear from the beginning that multiple
centers would need to be involved, both for the necessary
broad expertise they provided and also to provide suffi-
cient family data for adequate power. When COGA was
first conceived, it was realized that the project would be
long term. The protocol was well thought out, with strict
adherence to ascertainment, assessment, and data man-
agement. Sharing of results and problems was seen to
be very important, and members were enthusiastically
collaborative.
COGA studies have shown that multiple approaches
and multiple phenotypes can also be useful both for
replication purposes, and, more importantly, to find sub-
types (endophenotypes). The latter is important if there
is genetic heterogeneity, for example, a number of major
loci each involved in a specific phenotype. In the case
of alcoholism, it appears that electrophysiological var-
iables may be determined by some of the same loci in-
volved in alcohol dependence.
A number of other organisms have been used to iden-
tify genes for alcoholism. A strain of rats developed at
Indiana University by T.-K. Li and colleagues have been
divergently selected for their preference (P strain) or lack
of preference (NP strain) for alcohol. A QTL for alcohol
preference has been mapped to a region on rat chro-
mosome 4 that includes the neuropeptide Y (NPY) locus
(Bice et al. 1998). Mutations in NPY cause antisocial
behavior in Caenorhabditis elegans.
What can we expect in the future? While progress in
locating genes for complex disorders has been very slow
and frustrating, I believe we are now at a turning point.
A major development is the utilization of SNPs. They
are abundant in the genome, allowing relatively very fine
mapping of genes. They are present in coding and non-
coding, as well as regulatory regions, of genes. Highly
efficient automated techniques are now available for
high-throughput genotyping. I believe SNPs and CHIPS
are our salvation. Multiple loci can be assembled into
haplotypes, which makes the region highly polymorphic
and, in many cases, population specific. A HapMap pro-
ject is under way to construct haplotypes across the ge-
nome for the major races, which will undoubtedly ben-
efit the mapping of regions involved in complex diseases.
Regions of interest can be substantially narrowed to limit
the number of candidate genes to be sequenced. Case-
control studies that have been frowned on by many ge-
neticists due to questionable results, often due to strat-
ification, can now be used in a much more meaningful
manner in conjunction with SNP haplotypes. Linkage
disequilibrium studies are much more likely to locate
susceptibility genes. Witness the success of Graeme Bell’s
group in type 2 diabetes mellitus by finding an associ-
ation with the gene encoding calpain-10, using 21 SNPs
located in the telomeric region of chromosome 2q (Hor-
ikawa et al. 2000).
For most complex disorders, the family data that are
available may not always be sufficient to provide enough
power, but, on the other hand, most families are being
updated, in many cases, with more precise phenotyping
and/or new approaches to look at subphenotypes now
being termed “endophenotypes.” Thus, it is important
to have good rapport with families from the outset. It
will be also important in the future that more collabo-
rative efforts take place with less secrecy, especially in
the commercial field, but this is probably wishful think-
ing on my part. We must remember that collaborative
research is much more efficient than individual scientists
“going it alone.”
New statistical methodologies will be forthcoming to
deal with novel types of populations and samples and,
hopefully, will be conservative in their conclusions. This
is important, since there will now be many more com-
parisons (multiple phenotypes and even more multiple
genotypes) resulting in many more type 1 errors leading
to false conclusions.
In the more distant future, health care providers will
be enriching personalized medicine with risk factors,
which will be easy to determine, and appropriate inter-
ventions will be available to those who wish to partake
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of them. Hopefully, such information will be available
to all who seek it, at a reasonable cost. This is likely to
happen if testing for risk factors is not subject to high-
cost royalties. Like many of you, I am very concerned
about gene patenting but am hopeful that risk-factor
genes will not be granted patents.
Education of the public and health care providers,
including genetic counselors, will be essential. This
should be an important part of our mission in the future.
Our society is planning to substantially upgrade its ed-
ucational mission. It is critical that all of us be involved
in this endeavor.
Finally, I leave you with two thoughts. If you are in
doubt about the power of your individual study, collab-
orate. For the public and health care delivery personnel
who are very likely to be in doubt on the relevance of
risk factors, educate.
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